Antroquinonol is under clinical development by Golden Biotechnology and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Antroquinonol’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 04 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Antroquinonol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Antroquinonol overview

Antroquinonol (Hocena) is under development for the treatment of relapsed acute myeloid leukemia, acute myeloid leukemia, non squamous non small cell lung cancer, metastasis pancreatic cancer, chronic hepatitis B, hepatocellular carcinoma, nonfamilial hypercholesterolemia, mixed hyperlipidemia and Alzheimer's disease. The drug candidate is a small molecule administered orally. It is a new chemical entity (NCE). The drug candidate is a ubiquinone derivate. It is a purified cyclohexenone compound from the extract of Antrodia camphorate. The drug candidate targets farnesyl transferase and down regulates PI3K and mTOR signaling pathways. It was also under development for atopic dermatitis. It was also under development for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pneumonia.

Golden Biotechnology overview

Golden Biotechnology (Golden Biotech) is a drug discovery and food supplement manufacturing company. The company develops and commercializes drugs and herbal supplements to prevent and treat several cancer diseases. It discovers new drugs for cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases from the screening platforms. Golden Biotech also offers products under brand names liverty, zsaino, rasle and umooze. It has trial clinical centers for the completion of the Covid-19 in the US, Peru and Argentina. The company markets its products in China, Taiwan, the US, Malaysia and Japan, among others. Golden Biotech is headquartered in New Taipei, Taiwan.

Quick View Antroquinonol LOA Data

Report Segments
  • Innovator
Drug Name
  • Antroquinonol
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.